EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 342 filers reported holding EXELIXIS INC in Q2 2021. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $385,585 | -0.8% | 17,160 | +4.8% | 0.00% | -33.3% |
Q1 2024 | $388,555 | -6.4% | 16,374 | -5.4% | 0.00% | 0.0% |
Q4 2023 | $415,147 | +24.3% | 17,305 | +13.2% | 0.00% | 0.0% |
Q3 2023 | $333,977 | -31.1% | 15,285 | -39.8% | 0.00% | -40.0% |
Q2 2023 | $484,954 | +15.0% | 25,377 | +16.8% | 0.01% | 0.0% |
Q1 2023 | $421,702 | +8.0% | 21,726 | -10.8% | 0.01% | +66.7% |
Q4 2022 | $390,510 | -99.9% | 24,346 | -50.8% | 0.00% | -25.0% |
Q3 2022 | $388,388,000 | +75905.5% | 49,466 | +101.6% | 0.00% | -20.0% |
Q2 2022 | $511,000 | -0.4% | 24,538 | +8.4% | 0.01% | 0.0% |
Q1 2022 | $513,000 | +40.9% | 22,645 | +13.8% | 0.01% | +25.0% |
Q4 2021 | $364,000 | +24.2% | 19,894 | +43.6% | 0.00% | +33.3% |
Q3 2021 | $293,000 | +8.1% | 13,858 | -6.9% | 0.00% | 0.0% |
Q2 2021 | $271,000 | -16.1% | 14,878 | +4.1% | 0.00% | -25.0% |
Q1 2021 | $323,000 | -15.4% | 14,293 | -24.5% | 0.00% | 0.0% |
Q4 2020 | $382,000 | -99.9% | 18,920 | +32.1% | 0.00% | -42.9% |
Q3 2020 | $350,000,000 | – | 14,324 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |